Clinical Trial Information

Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway Altered Malignancies

Category: Solid Tumors
Status: Active
Starts: Aug 5, 2025
Trial Number: ULI-EAP-100

Principal Investigator: Jose Galeas, MD

Research Nurse: Wendy Blount, RN, MSN

Description of Trial:

The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.

NCT04566393
Click here for additional information.